{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:25Z","timestamp":1787020825196,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Millennium Pharmaceuticals, Inc.","award":["ID0E3FAG650"],"award-info":[{"award-number":["ID0E3FAG650"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13045-015-0198-1","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T22:52:08Z","timestamp":1441234328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacokinetics and safety of ixazomib plus lenalidomide\u2013dexamethasone in Asian patients with relapsed\/refractory myeloma: a phase 1 study"],"prefix":"10.1186","volume":"8","author":[{"given":"Neeraj","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S. M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chor Sang","family":"Chim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Min","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixie-Lee","family":"Esseltine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"198_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-540-85772-3_2","volume":"183","author":"N Becker","year":"2011","unstructured":"Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25\u201335.","journal-title":"Recent Results Cancer Res"},{"issue":"7","key":"198_CR2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol. 2014;89(7):751\u20136.","journal-title":"Am J Hematol"},{"issue":"9758","key":"198_CR3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075\u201385.","journal-title":"Lancet"},{"issue":"1","key":"198_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","volume":"120","author":"M Cavo","year":"2012","unstructured":"Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9\u201319.","journal-title":"Blood"},{"issue":"9","key":"198_CR5","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801\u20139.","journal-title":"Blood"},{"issue":"19","key":"198_CR6","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375\u201382.","journal-title":"Blood"},{"issue":"5","key":"198_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679\u201386.","journal-title":"Blood"},{"issue":"20","key":"198_CR8","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"L Garderet","year":"2012","unstructured":"Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005\u201304 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475\u201382.","journal-title":"J Clin Oncol"},{"issue":"10","key":"198_CR9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma. Blood. 2014;123(10):1461\u20139.","journal-title":"Blood"},{"issue":"2","key":"198_CR10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"5","key":"198_CR11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00277-009-0871-y","volume":"89","author":"HS Eom","year":"2010","unstructured":"Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, et al. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2010;89(5):489\u201397.","journal-title":"Ann Hematol"},{"issue":"9983","key":"198_CR12","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2014","unstructured":"Rollig C, Knop S, Bornhauser M. Multiple myeloma. The Lancet. 2014;385(9983):2197\u2013208.","journal-title":"The Lancet"},{"issue":"7","key":"198_CR13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma. Blood. 2014;124(7):1047\u201355.","journal-title":"Blood"},{"issue":"13","key":"198_CR14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15(13):1503\u201312.","journal-title":"Lancet Oncol"},{"issue":"7","key":"198_CR15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","volume":"124","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients. Blood. 2014;124(7):1038\u201346.","journal-title":"Blood"},{"issue":"21","key":"198_CR16","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood.V124.21.3450.3450","volume":"124","author":"G Merlini","year":"2014","unstructured":"Merlini G, Sanchorawala V, Jeffrey ZA, Kukreti V, Schoenland SO, Jaccard A, et al. Long-term outcome of a phase 1 study of the investigational oral proteasome inhibitor (PI) ixazomib at the recommended phase 3 dose (RP3D) in patients (Pts) with relapsed or refractory systemic light-chain (AL) amyloidosis (RRAL). Blood. 2014;124(21):3450.","journal-title":"Blood"},{"issue":"2","key":"198_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5414\/CPP38053","volume":"38","author":"JA Johnson","year":"2000","unstructured":"Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000;38(2):53\u201360.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"198_CR18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","volume":"84","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"198_CR19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpt.61","volume":"97","author":"A Ramamoorthy","year":"2015","unstructured":"Ramamoorthy A, Pacanowski M, Bull J, Zhang L. Racial\/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"198_CR20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bcp.12542","volume":"79","author":"N Gupta","year":"2014","unstructured":"Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol. 2014;79(5):789\u2013800.","journal-title":"Br J Clin Pharmacol"},{"key":"198_CR21","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1038\/bcj.2014.71","volume":"4","author":"SE Assouline","year":"2014","unstructured":"Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, et al. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed\/refractory lymphoma. Blood Cancer J. 2014;4:e251.","journal-title":"Blood Cancer J"},{"issue":"3","key":"198_CR22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","volume":"84","author":"SP Myrand","year":"2008","unstructured":"Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, et al. Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"198_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/2168479013517892","volume":"48","author":"M Oishi","year":"2014","unstructured":"Oishi M, Hiro S, Matsuoka N, Hotta S, Ono R, Mori Y, et al. A comparison of the pharmacokinetics and drug safety among East Asian populations. Ther Innov Regul Sci. 2014;48(3):393\u2013403.","journal-title":"Ther Innov Regul Sci"},{"key":"198_CR24","unstructured":"Merlini G, Sanchorawala V, Zonder J A, Kukreti V, Schoenland S O, Jaccard A, et al. MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): Results of a Phase 1 Study. http:\/\/myeloma.org\/pdfs\/Merlini-731-3876.pdf . Accessed January 20, 2015."},{"issue":"17","key":"198_CR25","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","volume":"31","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189\u2013204.","journal-title":"J Clin Oncol"},{"issue":"9","key":"198_CR26","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0198-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T18:58:10Z","timestamp":1599505090000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/8\/1\/103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1186\/s13045-015-0198-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]},"article-number":"103"}}